^
    Back
    Association details:
    Biomarker:PIK3CA Q546K
    Cancer:Thyroid Gland Carcinoma
    Drug:Caprelsa (vandetanib) (Multi-tyrosine kinase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    ESMO Open
    Title:

    Safety and activity of vandetanib in combination with everolimus in patients with advanced solid tumors: a phase I study

    Published date:
    03/12/2021
    Excerpt:
    Patients were enrolled at five dose levels using 100 mg of VAN orally daily and 2.5 mg of EV orally daily for 28 days as starting doses…one patient with a metastatic poorly differentiated thyroid carcinoma with a PIK3CA Q546K mutation had a 37% reduction in tumor size from baseline and remained on therapy for 14 cycles.
    Secondary therapy:
    everolimus
    DOI:
    10.1016/j.esmoop.2021.100079